Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

IEC 2021 | GABAergic signaling in autism spectrum disorders

James Clement, PhD, Jawaharlal Nehru Centre for Advanced Scientific Research, Bangalore, India, discusses the role of GABAergic signaling in autism spectrum disorders. Studies from autistic mouse models and patients have suggested that γ-Aminobutyric acid (GABA) is one of the major therapeutic targets for autism spectrum disorders due to GABAergic neuron functions being affected as a result of mutations in genes involved with autism. Dr Clement talks on the activation and inhibitory effects of GABA and the outcomes of disrupting the GABAergic signaling pathway. This interview took place during the 34th International Epilepsy Congress, 2021.